Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Issued a Decision on the Regulation of Surgical Operations in Specialized Hospitals and Reminded Beauty Centers of the Legal Deadline Given until August to Settle their Situation

 
Deputy Prime Minister Health Minister Ghassan Hasbani held a press conference in his office at the Ministry of Public Health, Bir Hassan during which he tackled the organizational frames of beauty Centers and specialized hospitals.
He started by saying: “After the repetitive complaints received by the Ministry of Public Health on accidents and infringements occurring in the sector of Aesthetic Medicine, and as a result of what happened yesterday after the liposuction operation in a specialized hospital, we realized that it is our duty to inform you about the approach of the Ministry to the regulation of aesthetic sector and the actions taken and that being completed through regulatory actions."
 
Beauty Centers

He added: "The Ministry of Public Health followed up the work of the Parliamentary Health Commission for the regulation of Medical Beauty Centers licenses that resulted in the issuance of decision No. 30 of 10 February 2017, which was published in The Official gazette on February 16, 2017.  The Definition of Aesthetic Medicine, its centers and the medical work they are authorized to carry out are regulated by Law which has determined the medical specializations that have the right to hold a permission to practice the profession of Aesthetic medicine. According to the law, the existing Beauty Centers are given a 6 month period to regularize their legal situation as of the date of the publication of this law, i.e. 16 August 2017, under penalty of closing these centers by a decision of Health Minister.

Specialized Hospitals

Health Minister added that he has issued a regulatory decision for specialized hospitals related to the regulation of surgeries which stipulates the following:
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not be carried out in places other than specialized hospitals which include an intensive care division which holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent. 
Hasbani stressed that this decision will be immediately communicated to all concerned parties.

Death Case

Hasbani talked also about the recent tragic death of the woman who underwent a liposuction opertaion in a specialized hospital and said: “the Public Prosecution and the Syndicate of Physicians have launched investigations and the Ministry of Public Health has started to investigate and complete the files. The Committee of investigations will meet in the Ministry in order to consider the details of this case and provide consultancies to the Syndicate and Justice where needed.
    ...
    13
    ...
ATC Name B/G Ingredients Dosage Form Price
L01ED04 ALUNBRIG B Brigatinib - 90mg 90mg Tablet, film coated 261,678,963 L.L
L01ED04 ALUNBRIG B Brigatinib - 180mg 180mg Tablet, film coated 409,120,926 L.L
L01EG02 AFINITOR B Everolimus - 5mg 5mg Tablet 154,115,122 L.L
L01EG02 AFINITOR B Everolimus - 10mg 10mg Tablet 221,857,193 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution + solvent 34,948,930 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 150mg 150mg Injectable powder for concentrate for solution 21,176,745 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrated solution 75,875,312 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 400mg 400mg Injectable concentrated solution 75,875,312 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrated solution 24,533,456 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 100mg 100mg Injectable concentrated solution 24,533,456 L.L
L01FX05 ADCETRIS BioTech Brentuximab Vedotin - 50mg 50mg Injectable powder for concentrate for solution L.L
L01FX05 ADCETRIS BioTech Brentuximab Vedotin - 50mg 50mg Injectable powder for concentrate for solution 298,266,862 L.L
L01XG01 ALVOCADE G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 14,169,600 L.L
L01XK52 AKEEGA B Niraparib - 100mg, Abiraterone acetate - 500mg Tablet, film coated 519,366,124 L.L
L01XK52 AKEEGA B Niraparib - 50mg, Abiraterone acetate - 500mg Tablet, film coated 519,366,124 L.L
L01XX35 ANAGRELIDE BIOGARAN G Anagrelide - 0.5mg 0.5mg Capsule 15,754,068 L.L
L02BG03 ARIMIDEX B Anastrozole - 1mg 1mg Tablet, film coated 3,202,377 L.L
L02BG03 ANASTROZOL GP PHARM G Anastrozole - 1mg 1mg Tablet, film coated 1,181,238 L.L
L02BG03 ANASTROZOLE ARROW LAB G Anastrozole - 1mg 1mg Tablet 1,552,138 L.L
L02BG03 ANASTROZOLE BIOGARAN G Anastrozole - 1mg 1mg Tablet, coated 3,800,387 L.L
L02BG03 APO-ANASTROZOLE G Anastrozole - 1mg 1mg Tablet 2,615,118 L.L
L02BG04 APO-LETROZOLE G Letrozole - 2.5mg 2.5mg Tablet 1,962,010 L.L
L02BX03 ABLAX 250 G Abiraterone acetate - 250mg 250mg Tablet L.L
L02BX03 ABLAX 500 G Abiraterone acetate - 500mg 500mg Tablet L.L
L02BX03 ABIRATERONE ACETATE NEAPOLIS G Abiraterone acetate - 250mg 250mg Tablet 75,418,662 L.L
L02BX03 ABIRATERONE ACETATE SPC G Abiraterone acetate - 250mg 250mg Tablet, film coated 73,748,373 L.L
L02BX03 ABLAX 250 G Abiraterone acetate - 250mg 250mg Tablet 45,056,853 L.L
L02BX03 ABREMIA G Abiraterone acetate - 250mg 250mg Tablet 77,478,802 L.L
L02BX03 ABLAX 500 G Abiraterone acetate - 500mg 500mg Tablet 45,056,853 L.L
L02BX03 APO-ABIRATERONE G Abiraterone acetate - 500mg 500mg Tablet, film coated 46,110,590 L.L
    ...
    13
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026